<sup>177</sup>Lu-前列腺特异性膜抗原放射性配体疗法治疗前列腺癌临床应用专家共识

¹⁷⁷Lu-前列腺特异性膜抗原放射性配体疗法治疗前列腺癌临床应用专家共识

摘要: ¹⁷⁷Lu标记的前列腺特异性膜抗原（prostate specific membrane antigen，PSMA）放射性配体疗法已在国外获批应用于晚期前列腺癌治疗，且正在国内开展多项临床试验。专家组参考国外经验和观点，并结合国内临床实践和实测数据，形成¹⁷⁷Lu-PSMA放射性配体疗法在前列腺癌临床应用中的专家共识。

Abstract: ¹⁷⁷Lu- prostate specific membrane antigen (PSMA) radio-ligand therapy has been approved abroad for advanced prostate cancer and has been in several clinical trials in China. Based on domestic clinical practice and experimental data and referred to international experience and viewpoints, the expert group forms a consensus on the clinical application of ¹⁷⁷Lu-PSMA radio-ligand therapy in prostate cancer to guide clinical practice.